Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin vs N-Acetylcysteine for ATD-induced Hepatotoxicity
NCT07058090Phase 1Not yet recruiting
- Sponsor
- Liaquat National Hospital & Medical College
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of silymarin and acetylcysteine in drug induced liver injury (DILI) (3 arms), sponsored by Liaquat National Hospital & Medical College. Primary endpoint: Anti-Tuberculous Drug induced Hepatotoxicity at 14 days. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
silymarinacetylcysteine
03
Conditions
drug induced liver injury (DILI)
Beyond the preview
Go deeper on NCT07058090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07058090.